Zobrazeno 1 - 10
of 119
pro vyhledávání: '"Gross' disease"'
Autor:
Ashish V. Chintakuntlawar, Daniel J. Ma, K. Price, David M. Routman, Q. Zhai, B.C. May, A. Schmitt, Thomas H. Nagel, Michael L. Hinni, Robert L. Foote, S. Ebrahimi, M. Neben Wittich, Lisa A. McGee, J.C. Rwigema, Yolanda I. Garces, Samir H. Patel, J.J. Garcia
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e413-e414
PURPOSE/OBJECTIVE(S) Salivary duct carcinomas (SDC) make up < 2% of salivary duct tumors but are very aggressive with a low 5-year survival rate of 35%. This series reports long term outcomes of patients with SDC treated at a single institution. MATE
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::091cae232bc0c31479556d7973284128
https://doi.org/10.1016/j.ijrobp.2021.07.1188
https://doi.org/10.1016/j.ijrobp.2021.07.1188
Autor:
Ann W. Silk, Roy B. Tishler, Danielle N. Margalit, Glenn J. Hanna, E Fite, Manisha Thakuria, James A. DeCaprio, Jonathan D. Schoenfeld, Charles H. Yoon
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S42-S43
Purpose/objective(s) Serum antibodies to the Merkel oncoprotein (AMERK) are expressed in approximately 50% of patients (pts) with MCC and can be used to monitor for recurrence. This study aimed to describe changes in AMERK levels after RT for MCC and
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e5c2c019471b2390b94e86047efbb44a
https://doi.org/10.1016/j.ijrobp.2021.07.119
https://doi.org/10.1016/j.ijrobp.2021.07.119
Autor:
Alex Gorbonos, Gopal N. Gupta, Bital Savir-Baruch, Abhishek A. Solanki, Matthew M. Harkenrider, Marcus L. Quek, C.J. Miller, Dennis Chan Md, Grant Harmon, Michael Woods, B.H. Lee
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e276-e277
PURPOSE/OBJECTIVE(S) We used the patterns of recurrence on 18F-fluciclovine PET/CT in post-prostatectomy patients enrolled in the LOCATE trial to evaluate how well the most recent NRG Oncology and Groupe Francophone de Radiotherapie Urologique (GFRU)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c1d4c144dc1f423e07f6da9e85e382dc
https://doi.org/10.1016/j.ijrobp.2021.07.893
https://doi.org/10.1016/j.ijrobp.2021.07.893
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e632-e633
Purpose/Objective(s) To report outcomes in patients with inoperable endometrial cancer (ECa) treated with definitive radiotherapy and perform a dosimetric comparison of organs at risk (OARs) for HDR brachytherapy (BT) vs SBRT boost in those who recei
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ce243ce39c24379fb9b94b6240e2c312
https://doi.org/10.1016/j.ijrobp.2021.07.1678
https://doi.org/10.1016/j.ijrobp.2021.07.1678
Autor:
Lillie L. Lin
Technological improvements in proton therapy planning and delivery have led to the expansion and testing of proton therapy for a variety of malignancies, including gynecologic. Combined-modality therapy is frequently delivered either in the adjuvant
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bf290990239a497135e1040cc93ad2f3
https://doi.org/10.1016/b978-0-323-73349-6.00020-0
https://doi.org/10.1016/b978-0-323-73349-6.00020-0
Autor:
C. Huntzinger, P. Olcott, Shervin M. Shirvani, Judy Bartlett-Roberto, Yevgen Voronenko, Thorsten Melcher, Samuel Mazin
Publikováno v:
The British Journal of Radiology
The emerging biological understanding of metastatic cancer and proof-of-concept clinical trials suggest that debulking all gross disease holds great promise for improving patient outcomes. However, ablation of multiple targets with conventional exter
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ad06a25f388257ad0737f9bbb42551de
https://pubmed.ncbi.nlm.nih.gov/33112685
https://pubmed.ncbi.nlm.nih.gov/33112685
Autor:
Anand Swaminath, Paul Wheatley-Price, Parneet Cheema, Cheryl Ho, Anthony Brade, Stephanie Snow, Normand Blais, Dr.Andrew G. Robinson
Publikováno v:
Cancer Treatment and Research Communications, Vol 25, Iss, Pp 100265-(2020)
Background The PACIFIC study established durvalumab as a standard of care for consolidation therapy in patients treated with radical intent chemoradiation for stage III inoperable non-small cell lung cancer. In clinical practice, many patients are no
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb703b404e6c57a59f178281d35f7fcc
https://pubmed.ncbi.nlm.nih.gov/33310367
https://pubmed.ncbi.nlm.nih.gov/33310367
Autor:
Riccardo Finotello, Aaron Harper, I. Amores-Fuster, Jean-Benoit Tanis, Laura Blackwood, David Killick
Publikováno v:
Veterinary and Comparative Oncology. 16:431-440
Mast cell tumours (MCTs) are commonly treated with radiation therapy, most often in a microscopic disease setting. Poorer outcomes are expected in patients with gross disease, and irradiation of gross disease may be associated with greater toxicity.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fc1e6a58d346b55bca971d8868f8802f
https://doi.org/10.1111/vco.12398
https://doi.org/10.1111/vco.12398
Autor:
T. Romaguera, S. Chundru, R. Herrera, A. Kaiser, M.D. Chuong, D. Alvarez, Rupesh Kotecha, J. Contreras, Matthew Hall, A. Gutierrez, J. McCulloch, K.E. Mittauer
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:S141
PURPOSE/OBJECTIVE(S) Emerging data suggest that ablative stereotactic magnetic resonance-guided adaptive radiation therapy (SMART) for inoperable pancreas cancer (PCa) achieves favorable local control (LC) and overall survival (OS) compared to non-ab
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::cbf5c8ba4d4241e3ec1cbd46bc412e05
https://doi.org/10.1016/j.ijrobp.2021.07.318
https://doi.org/10.1016/j.ijrobp.2021.07.318
Publikováno v:
International Journal of Radiation Oncology*Biology*Physics. 111:e263
Purpose/Objective(s) To assess the capability of 192Ir-based high-dose-rate brachytherapy (HDR-BT) versus 169Yb-based rotating shield brachytherapy (RSBT) for simultaneous whole prostate dose escalation with focal boost to dominant intraprostatic les
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::61fab89f4af728cb296f26bb162a5b0c
https://doi.org/10.1016/j.ijrobp.2021.07.864
https://doi.org/10.1016/j.ijrobp.2021.07.864